Simoes C
Braz J Anesthesiol. 2023; 73(2):125-127.
PMID: 36963956
PMC: 10068525.
DOI: 10.1016/j.bjane.2023.03.001.
Roden D, Van Driest S, Wells Q, Mosley J, Denny J, Peterson J
Circ Res. 2018; 122(9):1176-1190.
PMID: 29700066
PMC: 5926807.
DOI: 10.1161/CIRCRESAHA.117.310965.
Turner S, Crawford D, Ritchie M
Expert Rev Clin Pharmacol. 2010; 2(5):559-570.
PMID: 20221410
PMC: 2835152.
DOI: 10.1586/ecp.09.32.
Beasley H
Trans Am Ophthalmol Soc. 1973; 71:61-6; discussion 66-9.
PMID: 10949590
PMC: 1310482.
Byrick R, ROSE D, Ranganathan N
Can Anaesth Soc J. 1982; 29(1):50-4.
PMID: 6799180
DOI: 10.1007/BF03007948.
High skeletal muscle adenylate cyclase in malignant hyperthermia.
Willner J, Cerri C, Wood D
J Clin Invest. 1981; 68(5):1119-24.
PMID: 6271806
PMC: 370904.
DOI: 10.1172/jci110355.
Three cases of malignant hyperthermia with special consideration of management.
Britt B, Gordon R
Can Anaesth Soc J. 1969; 16(2):99-105.
PMID: 5773498
DOI: 10.1007/BF03005789.
Malignant hyperthermia.
KALOW W
Proc R Soc Med. 1970; 63(2):178-80.
PMID: 5440755
PMC: 1811296.
Malignant hyperpyrexia during anaesthesia: possible association with subclinical myopathy.
Isaacs H, BARLOW M
Br Med J. 1970; 1(5691):275-7.
PMID: 5416617
PMC: 1699352.
DOI: 10.1136/bmj.1.5691.275.
Serious sequelae of general anesthesia.
BYRD Jr B, DANIEL Jr R, Vasudeo P
Ann Surg. 1972; 175(5):673-84.
PMID: 5028484
PMC: 1355237.
DOI: 10.1097/00000658-197205000-00007.
Malignant hyperthermia: an investigation of five patients.
Britt B, KALOW W, Gordon A, HUMPHREY J, Rewcastle N
Can Anaesth Soc J. 1973; 20(4):431-67.
PMID: 4718353
DOI: 10.1007/BF03026208.
Malignant hyperpyrexia. Further muscle studies in asymptomatic carriers identified by creatinine phosphokinase screening.
Isaacs H, BARLOW M
J Neurol Neurosurg Psychiatry. 1973; 36(2):228-43.
PMID: 4708457
PMC: 1083559.
DOI: 10.1136/jnnp.36.2.228.
Rigidity, hyperpyrexia and coma following fluphenazine enanthate.
Meltzer H
Psychopharmacologia. 1973; 29(4):337-46.
PMID: 4707025
DOI: 10.1007/BF00429281.
Clinical, electrophysiological and pathological studies on malignant hyperpyrexia.
Bradley W, Ward M, Murchison D, Hall L, Woolf N
Proc R Soc Med. 1973; 66(1 Pt 1):67-8.
PMID: 4690062
PMC: 1644375.
Clinical and genetic aspects of malignant hyperpyrexia.
Tyrrell J, SUMNER D
Proc R Soc Med. 1973; 66(1 Pt 1):63-6.
PMID: 4690060
PMC: 1644366.
Malignant hyperthermia: a case report of successful management.
Ratzlaff E, Jenkins L
Can Anaesth Soc J. 1972; 19(5):549-56.
PMID: 4647162
DOI: 10.1007/BF03005815.
Malignant hyperthermia: a pharmacogenetic disease of skeletal and cardiac muscle.
Britt B
Anesth Prog. 1974; 21(4):108-10.
PMID: 4527005
PMC: 2515746.
Hereditary malignant hyperpyrexia associated with muscle adenylate kinase deficiency.
Schmitt J, Schmidt K, Ritter H
Humangenetik. 1974; 24(3):253-7.
PMID: 4374418
DOI: 10.1007/BF00283595.
Malignant hyperthermia: aetiology unknown.
Britt B, KALOW W
Can Anaesth Soc J. 1970; 17(4):316-30.
PMID: 4317096
DOI: 10.1007/BF03004695.
Malignant hyperthermia--an investigation of three patients.
Britt B
Ann R Coll Surg Engl. 1971; 48(2):73-5.
PMID: 4251636
PMC: 2387803.